AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma

Opinion
Video

Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.

Recent Videos
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
4 experts in this video
4 experts in this video
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content